nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Trismus—Riluzole—amyotrophic lateral sclerosis	0.0239	0.0474	CcSEcCtD
L-DOPA—PSIP1—hindbrain—amyotrophic lateral sclerosis	0.0213	0.0779	CbGeAlD
L-DOPA—Dementia—Riluzole—amyotrophic lateral sclerosis	0.0194	0.0386	CcSEcCtD
L-DOPA—SLC7A8—tongue—amyotrophic lateral sclerosis	0.0183	0.067	CbGeAlD
L-DOPA—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0165	0.0327	CcSEcCtD
L-DOPA—DDC—nerve—amyotrophic lateral sclerosis	0.0162	0.0593	CbGeAlD
L-DOPA—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.016	0.0318	CcSEcCtD
L-DOPA—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.016	0.0318	CcSEcCtD
L-DOPA—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.0152	0.0301	CcSEcCtD
L-DOPA—PSIP1—embryo—amyotrophic lateral sclerosis	0.0133	0.0487	CbGeAlD
L-DOPA—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.0131	0.026	CcSEcCtD
L-DOPA—PSIP1—brainstem—amyotrophic lateral sclerosis	0.0122	0.0447	CbGeAlD
L-DOPA—DDC—hindbrain—amyotrophic lateral sclerosis	0.0121	0.0444	CbGeAlD
L-DOPA—DRD1—nerve—amyotrophic lateral sclerosis	0.0119	0.0436	CbGeAlD
L-DOPA—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0234	CcSEcCtD
L-DOPA—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.0116	0.023	CcSEcCtD
L-DOPA—Delusion—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0224	CcSEcCtD
L-DOPA—Mania—Riluzole—amyotrophic lateral sclerosis	0.011	0.0218	CcSEcCtD
L-DOPA—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.0106	0.021	CcSEcCtD
L-DOPA—PSIP1—medulla oblongata—amyotrophic lateral sclerosis	0.0085	0.0311	CbGeAlD
L-DOPA—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00816	0.0162	CcSEcCtD
L-DOPA—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00797	0.0158	CcSEcCtD
L-DOPA—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00769	0.0153	CcSEcCtD
L-DOPA—DDC—embryo—amyotrophic lateral sclerosis	0.00759	0.0278	CbGeAlD
L-DOPA—PSIP1—spinal cord—amyotrophic lateral sclerosis	0.00758	0.0278	CbGeAlD
L-DOPA—DRD2—nerve—amyotrophic lateral sclerosis	0.00703	0.0257	CbGeAlD
L-DOPA—DDC—brainstem—amyotrophic lateral sclerosis	0.00695	0.0255	CbGeAlD
L-DOPA—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00685	0.0136	CcSEcCtD
L-DOPA—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00671	0.0133	CcSEcCtD
L-DOPA—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00646	0.0128	CcSEcCtD
L-DOPA—PSIP1—nervous system—amyotrophic lateral sclerosis	0.00639	0.0234	CbGeAlD
L-DOPA—PSIP1—central nervous system—amyotrophic lateral sclerosis	0.00615	0.0225	CbGeAlD
L-DOPA—PSIP1—cerebellum—amyotrophic lateral sclerosis	0.00601	0.022	CbGeAlD
L-DOPA—Purpura—Riluzole—amyotrophic lateral sclerosis	0.006	0.0119	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00578	0.0115	CcSEcCtD
L-DOPA—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00578	0.0115	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00574	0.0114	CcSEcCtD
L-DOPA—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00565	0.0112	CcSEcCtD
L-DOPA—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0055	0.0109	CcSEcCtD
L-DOPA—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00544	0.0108	CcSEcCtD
L-DOPA—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00528	0.0105	CcSEcCtD
L-DOPA—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00527	0.0193	CbGeAlD
L-DOPA—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00512	0.0102	CcSEcCtD
L-DOPA—DRD1—brainstem—amyotrophic lateral sclerosis	0.00511	0.0187	CbGeAlD
L-DOPA—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.005	0.00993	CcSEcCtD
L-DOPA—PSIP1—brain—amyotrophic lateral sclerosis	0.00488	0.0179	CbGeAlD
L-DOPA—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00487	0.00967	CcSEcCtD
L-DOPA—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00462	0.00917	CcSEcCtD
L-DOPA—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00455	0.00903	CcSEcCtD
L-DOPA—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00452	0.00898	CcSEcCtD
L-DOPA—Depression—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00883	CcSEcCtD
L-DOPA—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00439	0.00873	CcSEcCtD
L-DOPA—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00868	CcSEcCtD
L-DOPA—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00868	CcSEcCtD
L-DOPA—SLC7A5—medulla oblongata—amyotrophic lateral sclerosis	0.00434	0.0159	CbGeAlD
L-DOPA—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00433	0.0086	CcSEcCtD
L-DOPA—SLC7A8—nervous system—amyotrophic lateral sclerosis	0.00421	0.0154	CbGeAlD
L-DOPA—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00826	CcSEcCtD
L-DOPA—DRD4—brain—amyotrophic lateral sclerosis	0.00406	0.0149	CbGeAlD
L-DOPA—SLC7A8—central nervous system—amyotrophic lateral sclerosis	0.00405	0.0148	CbGeAlD
L-DOPA—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00799	CcSEcCtD
L-DOPA—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00797	CcSEcCtD
L-DOPA—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.004	0.00795	CcSEcCtD
L-DOPA—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00791	CcSEcCtD
L-DOPA—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00791	CcSEcCtD
L-DOPA—SLC7A8—cerebellum—amyotrophic lateral sclerosis	0.00396	0.0145	CbGeAlD
L-DOPA—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00785	CcSEcCtD
L-DOPA—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00392	0.00779	CcSEcCtD
L-DOPA—SLC7A5—spinal cord—amyotrophic lateral sclerosis	0.00387	0.0142	CbGeAlD
L-DOPA—DRD3—nervous system—amyotrophic lateral sclerosis	0.00374	0.0137	CbGeAlD
L-DOPA—DDC—nervous system—amyotrophic lateral sclerosis	0.00364	0.0133	CbGeAlD
L-DOPA—DRD3—central nervous system—amyotrophic lateral sclerosis	0.0036	0.0132	CbGeAlD
L-DOPA—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00357	0.0071	CcSEcCtD
L-DOPA—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00702	CcSEcCtD
L-DOPA—DDC—central nervous system—amyotrophic lateral sclerosis	0.00351	0.0128	CbGeAlD
L-DOPA—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00696	CcSEcCtD
L-DOPA—DRD5—nervous system—amyotrophic lateral sclerosis	0.0035	0.0128	CbGeAlD
L-DOPA—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00343	0.00682	CcSEcCtD
L-DOPA—Tension—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00679	CcSEcCtD
L-DOPA—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00677	CcSEcCtD
L-DOPA—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00672	CcSEcCtD
L-DOPA—DRD5—central nervous system—amyotrophic lateral sclerosis	0.00337	0.0124	CbGeAlD
L-DOPA—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00669	CcSEcCtD
L-DOPA—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00665	CcSEcCtD
L-DOPA—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00648	CcSEcCtD
L-DOPA—SLC7A5—nervous system—amyotrophic lateral sclerosis	0.00326	0.0119	CbGeAlD
L-DOPA—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00642	CcSEcCtD
L-DOPA—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00639	CcSEcCtD
L-DOPA—SLC7A8—brain—amyotrophic lateral sclerosis	0.00322	0.0118	CbGeAlD
L-DOPA—Agitation—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00636	CcSEcCtD
L-DOPA—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00632	CcSEcCtD
L-DOPA—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00316	0.0116	CbGeAlD
L-DOPA—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00624	CcSEcCtD
L-DOPA—SLC7A5—central nervous system—amyotrophic lateral sclerosis	0.00314	0.0115	CbGeAlD
L-DOPA—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00312	0.0062	CcSEcCtD
L-DOPA—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00312	0.00619	CcSEcCtD
L-DOPA—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00611	CcSEcCtD
L-DOPA—SLC7A5—cerebellum—amyotrophic lateral sclerosis	0.00307	0.0112	CbGeAlD
L-DOPA—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00306	0.00608	CcSEcCtD
L-DOPA—Cough—Riluzole—amyotrophic lateral sclerosis	0.00304	0.00604	CcSEcCtD
L-DOPA—DRD2—brainstem—amyotrophic lateral sclerosis	0.00302	0.0111	CbGeAlD
L-DOPA—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00599	CcSEcCtD
L-DOPA—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00597	CcSEcCtD
L-DOPA—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00297	0.00589	CcSEcCtD
L-DOPA—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00587	CcSEcCtD
L-DOPA—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00582	CcSEcCtD
L-DOPA—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00576	CcSEcCtD
L-DOPA—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00569	CcSEcCtD
L-DOPA—DRD3—brain—amyotrophic lateral sclerosis	0.00286	0.0105	CbGeAlD
L-DOPA—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00564	CcSEcCtD
L-DOPA—Shock—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00555	CcSEcCtD
L-DOPA—DDC—brain—amyotrophic lateral sclerosis	0.00278	0.0102	CbGeAlD
L-DOPA—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00553	CcSEcCtD
L-DOPA—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00546	CcSEcCtD
L-DOPA—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00538	CcSEcCtD
L-DOPA—DRD5—brain—amyotrophic lateral sclerosis	0.00268	0.00981	CbGeAlD
L-DOPA—DRD1—nervous system—amyotrophic lateral sclerosis	0.00268	0.0098	CbGeAlD
L-DOPA—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00527	CcSEcCtD
L-DOPA—DRD1—central nervous system—amyotrophic lateral sclerosis	0.00258	0.00944	CbGeAlD
L-DOPA—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00511	CcSEcCtD
L-DOPA—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00507	CcSEcCtD
L-DOPA—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00503	CcSEcCtD
L-DOPA—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00502	CcSEcCtD
L-DOPA—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00497	CcSEcCtD
L-DOPA—SLC7A5—brain—amyotrophic lateral sclerosis	0.00249	0.00913	CbGeAlD
L-DOPA—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00491	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00487	CcSEcCtD
L-DOPA—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00487	CcSEcCtD
L-DOPA—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00483	CcSEcCtD
L-DOPA—Pain—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00483	CcSEcCtD
L-DOPA—SLC16A10—cerebellum—amyotrophic lateral sclerosis	0.00235	0.00861	CbGeAlD
L-DOPA—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00465	CcSEcCtD
L-DOPA—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00462	CcSEcCtD
L-DOPA—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00448	CcSEcCtD
L-DOPA—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00446	CcSEcCtD
L-DOPA—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00416	CcSEcCtD
L-DOPA—DRD1—brain—amyotrophic lateral sclerosis	0.00205	0.00749	CbGeAlD
L-DOPA—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00405	CcSEcCtD
L-DOPA—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00399	CcSEcCtD
L-DOPA—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00386	CcSEcCtD
L-DOPA—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00373	CcSEcCtD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00187	0.00836	CbGpPWpGaD
L-DOPA—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00181	0.00664	CbGeAlD
L-DOPA—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00359	CcSEcCtD
L-DOPA—Rash—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00356	CcSEcCtD
L-DOPA—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00356	CcSEcCtD
L-DOPA—Headache—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00354	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.0017	0.00762	CbGpPWpGaD
L-DOPA—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00335	CcSEcCtD
L-DOPA—PSIP1—Disease—TPK1—amyotrophic lateral sclerosis	0.00167	0.00746	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00163	0.00729	CbGpPWpGaD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC1A3—amyotrophic lateral sclerosis	0.0016	0.00716	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00159	0.00711	CbGpPWpGaD
L-DOPA—DRD2—nervous system—amyotrophic lateral sclerosis	0.00158	0.00579	CbGeAlD
L-DOPA—DRD2—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00153	0.00683	CbGpPWpGaD
L-DOPA—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00152	0.00558	CbGeAlD
L-DOPA—DDC—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00149	0.00668	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00149	0.00668	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00149	0.00668	CbGpPWpGaD
L-DOPA—DRD2—cerebellum—amyotrophic lateral sclerosis	0.00149	0.00545	CbGeAlD
L-DOPA—SLC7A5—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00148	0.00664	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00147	0.00659	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00142	0.00634	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00139	0.0062	CbGpPWpGaD
L-DOPA—PSIP1—Disease—VTA1—amyotrophic lateral sclerosis	0.00133	0.00596	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00129	0.00575	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00124	0.00553	CbGpPWpGaD
L-DOPA—DRD2—brain—amyotrophic lateral sclerosis	0.00121	0.00443	CbGeAlD
L-DOPA—DDC—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.00119	0.00534	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00118	0.00528	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.0011	0.00491	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00108	0.00485	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00106	0.00475	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00103	0.00461	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00103	0.0046	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00101	0.00452	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000957	0.00428	CbGpPWpGaD
L-DOPA—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00095	0.00348	CbGeAlD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000949	0.00425	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000926	0.00415	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000921	0.00412	CbGpPWpGaD
L-DOPA—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000915	0.00335	CbGeAlD
L-DOPA—PSIP1—Disease—PLB1—amyotrophic lateral sclerosis	0.000913	0.00409	CbGpPWpGaD
L-DOPA—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000894	0.00327	CbGeAlD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000854	0.00382	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000841	0.00377	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000828	0.00371	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000821	0.00367	CbGpPWpGaD
L-DOPA—PSIP1—Disease—VCP—amyotrophic lateral sclerosis	0.000814	0.00364	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000807	0.00361	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000807	0.00361	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000772	0.00345	CbGpPWpGaD
L-DOPA—CYP2D6—brain—amyotrophic lateral sclerosis	0.000726	0.00266	CbGeAlD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000719	0.00322	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000715	0.0032	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000704	0.00315	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000704	0.00315	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000671	0.003	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000663	0.00297	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000638	0.00285	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000628	0.00281	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000623	0.00279	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000596	0.00267	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CST3—amyotrophic lateral sclerosis	0.000584	0.00261	CbGpPWpGaD
L-DOPA—DDC—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000568	0.00254	CbGpPWpGaD
L-DOPA—DDC—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000568	0.00254	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000554	0.00248	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00055	0.00246	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000537	0.0024	CbGpPWpGaD
L-DOPA—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000535	0.0024	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000529	0.00237	CbGpPWpGaD
L-DOPA—DDC—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00052	0.00233	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000513	0.0023	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000511	0.00229	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000496	0.00222	CbGpPWpGaD
L-DOPA—DDC—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000483	0.00216	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000468	0.00209	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000468	0.00209	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00046	0.00206	CbGpPWpGaD
L-DOPA—DDC—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000454	0.00203	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000448	0.002	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000446	0.002	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00044	0.00197	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000428	0.00191	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CASP9—amyotrophic lateral sclerosis	0.000425	0.0019	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000424	0.0019	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000417	0.00187	CbGpPWpGaD
L-DOPA—DDC—Metabolism—DAO—amyotrophic lateral sclerosis	0.000411	0.00184	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000405	0.00181	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000402	0.0018	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000385	0.00173	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000381	0.0017	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000377	0.00169	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000364	0.00163	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000364	0.00163	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ERBB4—amyotrophic lateral sclerosis	0.000363	0.00163	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00034	0.00152	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000337	0.00151	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000335	0.0015	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000327	0.00146	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000324	0.00145	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000313	0.0014	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000311	0.00139	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000293	0.00131	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000289	0.00129	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSR—amyotrophic lateral sclerosis	0.000287	0.00129	CbGpPWpGaD
L-DOPA—PSIP1—Disease—APOE—amyotrophic lateral sclerosis	0.000281	0.00126	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000273	0.00122	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000272	0.00122	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000262	0.00117	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000256	0.00115	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000242	0.00108	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000236	0.00106	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000223	0.000999	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000216	0.000968	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000213	0.000954	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000205	0.000915	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000204	0.000915	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000202	0.000903	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000195	0.000871	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000194	0.000867	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTGS2—amyotrophic lateral sclerosis	0.000193	0.000862	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000192	0.000861	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000192	0.00086	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000192	0.000859	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000189	0.000848	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000185	0.000828	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000182	0.000816	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000178	0.000798	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000177	0.00079	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000174	0.00078	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000172	0.00077	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00017	0.000763	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000168	0.000752	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000165	0.000737	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000157	0.000702	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000155	0.000694	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000154	0.000691	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000151	0.000676	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000148	0.000664	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000147	0.000658	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000146	0.000655	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000145	0.000649	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000142	0.000635	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000136	0.000608	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000135	0.000603	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000135	0.000602	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000134	0.0006	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000132	0.000589	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000131	0.000585	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000131	0.000585	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00013	0.000583	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00013	0.00058	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000128	0.000572	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000127	0.000567	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000126	0.000564	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000126	0.000564	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000121	0.000542	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.00012	0.000535	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000119	0.000535	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000117	0.000525	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000117	0.000524	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000117	0.000521	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000116	0.000518	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000116	0.000518	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000115	0.000513	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000114	0.000512	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000112	0.000501	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000111	0.000497	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000106	0.000477	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000105	0.000472	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000104	0.000467	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000104	0.000466	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000104	0.000465	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000103	0.000461	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000103	0.00046	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000103	0.000459	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000102	0.000455	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.99e-05	0.000447	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	9.65e-05	0.000432	CbGpPWpGaD
L-DOPA—DDC—Metabolism—APOE—amyotrophic lateral sclerosis	9.59e-05	0.000429	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.56e-05	0.000428	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.51e-05	0.000426	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	9.44e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.31e-05	0.000417	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	9.14e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.86e-05	0.000396	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.61e-05	0.000385	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.5e-05	0.00038	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.45e-05	0.000378	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.38e-05	0.000375	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.27e-05	0.00037	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.14e-05	0.000364	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	7.95e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.86e-05	0.000352	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.86e-05	0.000352	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.78e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.66e-05	0.000343	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.61e-05	0.000341	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.51e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.37e-05	0.00033	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.16e-05	0.00032	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.08e-05	0.000317	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.02e-05	0.000314	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.98e-05	0.000312	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.77e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.64e-05	0.000297	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	6.61e-05	0.000296	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.57e-05	0.000294	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.55e-05	0.000293	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	6.5e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	6.33e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.32e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.3e-05	0.000282	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.24e-05	0.000279	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.01e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.75e-05	0.000257	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.65e-05	0.000253	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.42e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.41e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.34e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.34e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.2e-05	0.000233	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.09e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.02e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.01e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.99e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.77e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.65e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.5e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.44e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.18e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.13e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.08e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.01e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.84e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.84e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.79e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.46e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.41e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.4e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.39e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.16e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.96e-05	0.000132	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.92e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.79e-05	0.000125	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.66e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.63e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.61e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.57e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.52e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.51e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.48e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.26e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.23e-05	9.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.2e-05	9.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.01e-05	8.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.9e-05	8.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.9e-05	8.48e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.71e-05	7.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.71e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.68e-05	7.54e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.51e-05	6.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.29e-05	5.77e-05	CbGpPWpGaD
